Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A

Mohammed Milhem, Nadim Mahmud, Donald Lavelle, Hiroto Araki, Joseph DeSimone, Yogen Saunthararajah, Ronald Hoffman

Research output: Contribution to journalArticlepeer-review

173 Scopus citations

Abstract

Efforts to change the fate of human hematopoietic stem cells (HSCs) and progenitor cells (HPCs) in vitro have met with limited success. We hypothesized that previously utilized in vitro conditions might result in silencing of genes required for the maintenance of primitive HSCs/HPCs. DNA methylation and histone deacetylation are components of an epigenetic program that regulates gene expression. Using pharmacologic agents in vitro that might possibly interfere with DNA methylation and histone deacetyletion, we attempted to maintain and expand cells with phenotypic and functional characteristics of primitive HSCs/HPCs. Human marrow CD34+ cells were exposed to a cytokine cocktail favoring differentiation in combination with 5aza 2′deoxycytidine (5azaD) and trichostatin A (TSA), resulting in a significant expansion of a subset of CD34+ cells that possessed phenotypic properties as well as the proliferative potential characteristic of primitive HSCs/HPCs. In addition, 5azaD- end TSA-pretreated cells but not the CD34+ cells exposed to cytokines alone retained the ability to repopulate immunodeficient mice. Our findings demonstrate that 5azaD and TSA can be used to alter the fate of primitive HSCs/HPCs during in vitro culture.

Original languageEnglish
Pages (from-to)4102-4110
Number of pages9
JournalBlood
Volume103
Issue number11
DOIs
StatePublished - 1 Jun 2004
Externally publishedYes

Fingerprint

Dive into the research topics of 'Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A'. Together they form a unique fingerprint.

Cite this